Stool donor qualification and collection from metastatic melanoma (MM) patients (pts) who have responded to checkpoint inhibitors (CPI) for manufacturing of fecal microbiota transplantation (FMT).

Elizabeth M. Burton,Isabella Claudia Glitza,Jennifer Mahoney,Jennifer R. Wortman,John Aunis,Kevin Litcofsky,David A. Cook,Lata Jayaraman,Ramy Ibrahim,Theresa M. LaVallee,Hussein Abdul-Hassan Tawbi,Jennifer A. Wargo

Stool donor qualification and collection from metastatic melanoma (MM) patients (pts) who have responded to checkpoint inhibitors (CPI) for manufacturing of fecal microbiota transplantation (FMT).

2019

Elizabeth M. Burton
Isabella Claudia Glitza
Jennifer Mahoney
Jennifer R. Wortman
John Aunis
Kevin Litcofsky
David A. Cook
Lata Jayaraman
Ramy Ibrahim
Theresa M. LaVallee
Hussein Abdul-Hassan Tawbi
Jennifer A. Wargo

TPS146Background: There have been remarkable improvements in responses rates (RR) and outcomes for pts with MM with the use of single agent CPIs. However, only 35% of pts respond to therapy and les...

Keywords:

Pathology
Oncology
Medicine
Internal medicine
Fecal bacteriotherapy
Melanoma
immune checkpoint inhibitors
metastatic melanoma
single agent

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations